These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

489 related items for PubMed ID: 16767301

  • 1. [Treatment of dyslipidemia: how and when to combine lipid lowering drugs].
    Schulz I.
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):344-59. PubMed ID: 16767301
    [Abstract] [Full Text] [Related]

  • 2. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A, Fisman EZ, Motro M, Adler Y.
    Adv Cardiol; 2008 Apr; 45():127-153. PubMed ID: 18230960
    [Abstract] [Full Text] [Related]

  • 3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 4. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
    Bajnok L.
    Orv Hetil; 2014 Jan 12; 155(2):62-8. PubMed ID: 24389322
    [Abstract] [Full Text] [Related]

  • 5. Combination therapy for combined dyslipidemia.
    Xydakis AM, Ballantyne CM.
    Am J Cardiol; 2002 Nov 20; 90(10B):21K-29K. PubMed ID: 12467937
    [Abstract] [Full Text] [Related]

  • 6. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
    Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajorunas DR, Davidson MH.
    Am J Cardiovasc Drugs; 2008 Nov 20; 8(2):69-81. PubMed ID: 18422390
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.
    Le NA, Jin R, Tomassini JE, Tershakovec AM, Neff DR, Wilson PW.
    J Am Heart Assoc; 2013 Aug 07; 2(4):e000037. PubMed ID: 23926117
    [Abstract] [Full Text] [Related]

  • 10. Management of dyslipidemia in women in the post-hormone therapy era.
    Mosca L.
    J Gen Intern Med; 2005 Mar 07; 20(3):297-305. PubMed ID: 15836536
    [Abstract] [Full Text] [Related]

  • 11. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R, Goldberg AC.
    Endocrinol Metab Clin North Am; 2009 Mar 07; 38(1):79-97. PubMed ID: 19217513
    [Abstract] [Full Text] [Related]

  • 12. Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.
    Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E.
    Vasc Health Risk Manag; 2007 Mar 07; 3(4):467-79. PubMed ID: 17969377
    [Abstract] [Full Text] [Related]

  • 13. Extended-release niacin or ezetimibe and carotid intima-media thickness.
    Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M.
    N Engl J Med; 2009 Nov 26; 361(22):2113-22. PubMed ID: 19915217
    [Abstract] [Full Text] [Related]

  • 14. Diabetic dyslipidemia: a practical guide to therapy.
    Tovar JM, Bazaldua OV, Loffredo A.
    J Fam Pract; 2008 Jun 26; 57(6):377-88. PubMed ID: 18544321
    [Abstract] [Full Text] [Related]

  • 15. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA.
    Int J Clin Pract; 2011 Jan 26; 65(1):82-101. PubMed ID: 21105969
    [Abstract] [Full Text] [Related]

  • 16. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR, Knight M.
    Clin Ther; 2015 Oct 01; 37(10):2153-79. PubMed ID: 26412799
    [Abstract] [Full Text] [Related]

  • 17. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?
    Drexel H.
    Fundam Clin Pharmacol; 2009 Dec 01; 23(6):687-92. PubMed ID: 19682084
    [Abstract] [Full Text] [Related]

  • 18. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005 Dec 01; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

  • 19. Combination therapy for dyslipidemia: safety and regulatory considerations.
    Davidson MH.
    Am J Cardiol; 2002 Nov 20; 90(10B):50K-60K. PubMed ID: 12467940
    [Abstract] [Full Text] [Related]

  • 20. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z.
    Nutr Metab Cardiovasc Dis; 2013 Sep 20; 23(9):799-807. PubMed ID: 23932901
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.